Next Investors logo grey

AHI looks to complete Physimax acquisition


Published 29-APR-2021 10:16 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Last week, Advanced Human Imaging (ASX:AHI)came out of trading halt to announce that it had agreed to acquire Israeli based Musculoskeletal Assessment (MSK) company Physimax Technologies Limited for US$6M.

AHI has now concluded the binding heads of agreement to acquire Physimax and will now turn its attention to conclude all due diligence on or before 21 May 2021.

Physimax has developed and patented a revolutionary video-based objective solution that tracks and improves MSK wellness via video capture using a mobile device.

Known as Advanced Musculoskeletal Assessment Artificial Intelligence, the technology addresses musculoskeletal conditions that affect 1.71 billion people worldwide.

In fact, musculoskeletal disorders such as lower back pain cause the highest burden on healthcare systems with a prevalence of 568 million people worldwide and these conditions are the leading contributor to disability worldwide, causing disability in 160 countries.

Why Physimax

Physimax offers a wide range of automated evidence-based functional movement tests, resulting in all-encompassing analytics that can lead to injury prevention and athletic performance enhancements. Physimax conducts comparative Athletic and musculoskeletal scores which are calculated in relation to the same level industry normative values, maximizing the accuracy of the results.

It is in a similar wheelhouse to AHI’s overall goal of assisting individuals, communities and populations live healthier lives, worldwide, through its BodyScan technology which enables users to privately check, track, and accurately assess their dimensions, solely using a smartphone.

AHI is effectively extending its footprint in remote health management.

“The musculoskeletal assessment space is seeing accelerated interest, with a number of insurance and carebased platforms having adopted Musculoskeletal assessment, being Dario Health, Hinge Health and Carrum Health, all now adding offerings within their customer care initiatives,” Vlado Bosanac, Chairman and Chief Executive Officer of Advanced Human Imaging, said.

“As I previously stated Physimax would be a welcome addition to the AHI MultiScan platform. The Physimax technology has seen broad acceptance of the application worldwide with over 250,000 scans performed to date.

“With the AHI on device 2D/3D capturing capabilities of our patented system, we anticipate that, should the acquisition proceed, we will further enhance the Physimax system in readiness for a global approach to these new capabilities.

“The Physimax technology is being used in multiple facets of care and Musculoskeletal enhancement throughout the US, Europe and Asia. The use of the platform is well documented and used by the NBA, Clinicians, US Military and Universities around the world.”

Bosanac says, AHI is actively looking for expansion opportunities similar to the pending Physimax acquisition, with a view to either a partnership, or when advantageous, acquisition.

It has certainly been active in this space lately, signing a marketing agreement with the owners of the WinScan App - China-Based, Tinjoy Biotech Limited and releasing the Original Fit Factory Ltd (TOFF) App integrated with AHI’s technology.

All this activity should augur well for AHI as it draws closer to its NASDAQ listing.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.